The inhibition of several components of terminal complement pathway results in C3 binding to PNH red blood cells
- 24 January 2024
- journal article
- letter
- Published by Wiley in American Journal of Hematology
- Vol. 99 (3) , 505-507
Abstract
C3 binding on PNH red blood cells after in vitro complement activation in normal and terminal complement depleted (∆5, ∆6, ∆9) sera: C3 binding, and the subsequent extravascular hemolysis, happens anytime there is a block of a component of the terminal complement pathway.Keywords
Funding Information
- Istituto Toscano Tumori
This publication has 11 references indexed in Scilit:
- Breakthrough Hemolysis in PNH with Proximal or Terminal Complement InhibitionNew England Journal of Medicine, 2022
- Long‐term safety and efficacy of ravulizumab in patients with paroxysmal nocturnal hemoglobinuria: 2‐year results from two pivotal phase 3 studiesEuropean Journal of Haematology, 2022
- How we(’ll) treat paroxysmal nocturnal haemoglobinuria: diving into the futureBritish Journal of Haematology, 2021
- Pegcetacoplan versus Eculizumab in Paroxysmal Nocturnal HemoglobinuriaNew England Journal of Medicine, 2021
- Outrageous prices of orphan drugs: a call for collaborationThe Lancet, 2018
- Eculizumab treatment: stochastic occurrence of C3 binding to individual PNH erythrocytesJournal of Hematology & Oncology, 2017
- Incomplete inhibition by eculizumab: mechanistic evidence for residual C5 activity during strong complement activationBlood, 2017
- Long‐term safety and efficacy of sustained eculizumab treatment in patients with paroxysmal nocturnal haemoglobinuriaBritish Journal of Haematology, 2013
- Persistently high quality of life conferred by coexisting congenital deficiency of terminal complement C9 in a paroxysmal nocturnal hemoglobinuria patientBlood, 2012
- Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumabBlood, 2009